西他列汀脱氟杂质4 | 486459-98-7

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 西他列汀脱氟杂质4
• 中文别名: 西格列汀氟杂质4
• 英文名称: (3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,5-difluorophenyl)butanoic acid
• 英文别名: N-Boc-4-(2,5-difluorophenyl)-3(R)-aminobutanoic acid；(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,5-difluorophenyl)butanoic acid；(R)-b-(Boc-amino)-2,5-difluorobenzenebutanoic acid；(3R)-4-(2,5-difluorophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid
• CAS: 486459-98-7
• 化学式: C₁₅H₁₉F₂NO₄
• 分子量: 315.317
• InChiKey: DYAISPAQPPRCQC-LLVKDONJSA-N

物化性质

• 沸点：
  442.9±45.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  西他列汀脱氟杂质4 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-1-[(R)-3-Amino-4-(2,5-difluoro-phenyl)-butyryl]-5-methyl-imidazolidin-4-one
  参考文献：
  名称：

  (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

  摘要：

  Replacement of the triazolopiperazine ring of sitagliptin (DPP-4 IC(50)=18nM) with 3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one gave dipeptidyl peptidase IV (DPP-4) inhibitor 1 which is potent (DPP-4 IC(50)=2.6nM), selective, and efficacious in an oral glucose tolerance test in mice. It was selected for extensive preclinical development as a potential back-up candidate to sitagliptin.

  DOI：

  10.1016/j.bmcl.2006.09.099
• 作为产物：
  描述：

  (R,S)-3-[(1,1-dimethylethoxycarbonyl)amino]-1-diazo-4-(2,5-difluoro-phenyl)butan-2-one 在 silver benzoate 、 N,N-二异丙基乙胺 、 水 、 lithium hydroxide 作用下， 以 甲醇 、 乙醇 、 正己烷 、 四氢呋喃 为溶剂， 反应 5.5h， 以360 mg的产率得到西他列汀脱氟杂质4
  参考文献：
  名称：

  BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

  摘要：

  本发明涉及一种抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，该化合物在治疗或预防二肽基肽酶-IV酶参与的疾病中具有用途，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。

  公开号：

  US20150359793A1

文献信息

• [EN] 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] DERIVES DE 3-AMINO-4-PHENYLBUTANOIQUE ACIDE UTILISES EN TANT QU'INHIBITEURS DE DIPEPTIDYL PEPTIDASE POUR LE TRAITEMENT OU LA PREVENTION DU DIABETE
  申请人：MERCK & CO INC

  公开号：WO2004058266A1

  公开（公告）日：2004-07-15

  The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及3-氨基-4-苯基丁酸衍生物，这些衍生物是二肽基肽酶-IV酶（'DP-IV抑制剂'）的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• [EN] TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES<br/>[FR] TETRAHYDROQUINOLONES ET AZA-ANALOGUES ASSOCIES UTILISES EN TANT QU'INHIBITEURS DE LA DPP-IV DANS LE TRAITEMENT DU DIABETE
  申请人：ASTRAZENECA AB

  公开号：WO2005123685A1

  公开（公告）日：2005-12-29

  Compound of formula (I) or a pharmaceutically-acceptable salt thereof, formula (I) wherein Ar is optionally substituted phenyl; R1 is selected from: formula a) or b) (wherein is a single or double bond); R5, R6, R7 and R8 are for example hydrogen or alkyl; R4 is selected from hydrogen, (3-4C)cycloalkyl and optionally substituted (1-4C)alkyl; R10 is for example selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl, hydroxy(1-4C)alkyl, (1-4C)alkoxy, aryl(1-4C)alkyl; Y is carbon and Ring A is optionally substituted phenylene; or each Y may independently be carbon or nitrogen and Ring A is optionally substituted 5- or 6-membered, heteroarylene ring; R11 is selected from hydrogen and optionally substituted phenyl; p is independently at each occurrence 0, 1 or 2; are described. Processes for making such compounds and their use as DPP-IV inhibitors in the treatment of diabetes are also described.

  化合物的化学式（I）或其药用可接受的盐，其中化学式（I）中Ar是可选择的取代苯基；R1选自：化学式a）或b）（其中是单键或双键）；R5、R6、R7和R8例如是氢或烷基；R4选自氢、（3-4C）环烷基和可选择的取代（1-4C）烷基；R10例如选自氢、（1-4C）烷基、（3-6C）环烷基（1-4C）烷基、羟基（1-4C）烷基、（1-4C）烷氧基、芳基（1-4C）烷基；Y是碳，环A是可选择的取代苯基；或每个Y可以独立地是碳或氮，环A是可选择的取代的5-或6-成员的杂芳烃环；R11选自氢和可选择的取代苯基；p在每次出现时独立地为0、1或2；描述了制备这类化合物的过程以及它们作为DPP-IV抑制剂在糖尿病治疗中的用途。
• [EN] PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] INHIBITEURS DE PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE UTILISES DANS LE TRAITEMENT DU DIABETE
  申请人：MERCK & CO INC

  公开号：WO2004007468A1

  公开（公告）日：2004-01-22

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种抑制二肽基肽酶IV酶（'DP-IV抑制剂'）的化合物，该化合物在治疗或预防涉及二肽基肽酶IV酶的疾病中具有用途，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在预防或治疗涉及二肽基肽酶IV酶的疾病中的用途。
• Synthesis of a β-Amino Acid Pharmacophore via a β-Lactam Intermediate
  作者：Rémy Angelaud、Yong-Li Zhong、Peter Maligres、Jaemoon Lee、David Askin

  DOI：10.1021/jo048249c

  日期：2005.3.1

  A stereoselective synthesis of (R)-β-amino acid 1 via a β-lactam intermediate is discussed.

  讨论了经由β-内酰胺中间体的立体选择性合成（R）-β-氨基酸1。
• Potent and selective proline derived dipeptidyl peptidase IV inhibitors
  作者：Scott D. Edmondson、Anthony Mastracchio、Maria Beconi、Lawrence F. Colwell、Bahanu Habulihaz、Huaibing He、Sanjeev Kumar、Barbara Leiting、Kathryn A. Lyons、Ann Mao、Frank Marsilio、Reshma A. Patel、Joseph K. Wu、Lan Zhu、Nancy A. Thornberry、Ann E. Weber、Emma R. Parmee

  DOI：10.1016/j.bmcl.2004.07.056

  日期：2004.10

  In-house screening of the Merck sample collection identified proline derived homophenylalanine 3 as a DPP-IV inhibitor with modest potency (DPP-IV IC50=1.9 microM). Optimization of 3 led to compound 37, which is among the most potent and selective DPP-IV inhibitors discovered to date.

  对Merck样品的内部筛选表明，脯氨酸衍生的高苯丙氨酸3作为DPP-IV抑制剂具有中等效力（DPP-IV IC50 = 1.9 microM）。对3的优化导致化合物37，它是迄今为止发现的最有效和选择性最强的DPP-IV抑制剂之一。